换肤

特宝生物

i问董秘

A03328

主营介绍

  • 主营业务：

    重组蛋白质及其长效修饰药物研发、生产及销售

  • 产品类型：

    生物制品

  • 产品名称：

    聚乙二醇干扰素α-2b注射液(商品名称:“派格宾”) 、 注射用重组人粒细胞巨噬细胞刺激因子(商品名称:“特尔立”) 、 重组人粒细胞刺激因子注射液(商品名称:“特尔津”) 、 注射用重组人白介素-11(商品名称:“特尔康”)

  • 经营范围：

    生物药品制造；其他未列明专业技术服务业（不含需经许可审批的事项）；其他未列明制造业（不含须经许可审批的项目）；生物技术推广服务；经营本企业自产产品的出口业务和本企业所需的机械设备、零配件、原辅材料的进口业务（不另附进出口商品目录），但国家限定公司经营或禁止进出口的商品及技术除外；经营各类商品和技术的进出口（不另附进出口商品目录），但国家限定公司经营或禁止进出口的商品及技术除外；其他未列明批发业（不含需经许可审批的经营项目）。

运营业务数据

最新公告日期：2019-03-27　
业务名称 2018-12-31 2017-12-31 2016-12-31
派格宾产量(支) 41.22万 18.59万 10.92万
派格宾销量(支) 34.13万 15.04万 9.95万
特尔康产量(支) 138.13万 103.44万 82.33万
特尔康销量(支) 125.48万 100.55万 94.29万
特尔津产量(支) 637.30万 492.74万 461.84万
特尔津销量(支) 588.34万 475.63万 457.12万
特尔立产量(支) 140.86万 124.95万 103.92万
特尔立销量(支) 132.03万 117.39万 107.31万

主营构成分析

报告期
报告期
{"2019-06-30":{"YYSR":{"1":[["\u751f\u7269\u5236\u5242","31820.39"]],"2":[["\u6d3e\u683c\u5bbe","14849.84"],["\u7279\u5c14\u6d25","8773.98"],["\u7279\u5c14\u5eb7","5655.70"],["\u7279\u5c14\u7acb","2540.87"]],"3":[["\u534e\u4e1c","10262.85"],["\u534e\u4e2d","5823.31"],["\u534e\u5317","3469.49"],["\u897f\u5317","3434.16"],["\u534e\u5357","3008.86"],["\u5176\u4ed6\u4e1a\u52a1\u603b\u8ba1",5821.71]]},"YYCB":{"1":[["\u751f\u7269\u5236\u5242","3946.98"]],"2":[["\u6d3e\u683c\u5bbe","2311.50"],["\u7279\u5c14\u6d25","998.75"],["\u7279\u5c14\u5eb7","350.85"],["\u7279\u5c14\u7acb","285.88"]],"3":[["\u534e\u4e1c","1449.09"],["\u534e\u4e2d","648.19"],["\u534e\u5317","404.71"],["\u897f\u5317","352.15"],["\u534e\u5357","432.18"],["\u5176\u4ed6\u4e1a\u52a1\u603b\u8ba1",660.67]]},"LRBL":{"1":[["\u751f\u7269\u5236\u5242","100.00"]],"2":[["\u6d3e\u683c\u5bbe","44.98"],["\u7279\u5c14\u6d25","27.89"],["\u7279\u5c14\u5eb7","19.03"],["\u7279\u5c14\u7acb","8.09"]],"3":[["\u534e\u4e1c","31.62"],["\u534e\u4e2d","18.57"],["\u534e\u5317","11.00"],["\u897f\u5317","11.06"],["\u534e\u5357","9.24"],["\u5176\u4ed6\u4e1a\u52a1\u603b\u8ba1",18.52]]}},"2018-12-31":{"YYSR":{"1":[["\u751f\u7269\u5236\u5242","44616.11"]],"2":[["\u6d3e\u683c\u5bbe","18736.55"],["\u7279\u5c14\u6d25","12741.22"],["\u7279\u5c14\u5eb7","8386.88"],["\u7279\u5c14\u7acb","4751.45"]],"3":[["\u534e\u4e1c","14055.40"],["\u534e\u4e2d","9529.27"],["\u897f\u5357","5424.29"],["\u534e\u5357","4249.43"],["\u4e1c\u5317","3688.48"],["\u5176\u4ed6\u4e1a\u52a1\u603b\u8ba1",7669.24]]},"YYCB":{"1":[["\u751f\u7269\u5236\u5242","5584.60"]],"2":[["\u6d3e\u683c\u5bbe","2894.46"],["\u7279\u5c14\u6d25","1658.01"],["\u7279\u5c14\u5eb7","486.26"],["\u7279\u5c14\u7acb","545.87"]],"3":[["\u534e\u4e1c","2128.19"],["\u534e\u4e2d","1172.97"],["\u897f\u5357","887.46"],["\u534e\u5357","499.04"],["\u4e1c\u5317","381.64"],["\u5176\u4ed6\u4e1a\u52a1\u603b\u8ba1",515.28]]},"LRBL":{"1":[["\u751f\u7269\u5236\u5242","100.00"]],"2":[["\u6d3e\u683c\u5bbe","40.59"],["\u7279\u5c14\u6d25","28.40"],["\u7279\u5c14\u5eb7","20.24"],["\u7279\u5c14\u7acb","10.77"]],"3":[["\u534e\u4e1c","30.56"],["\u534e\u4e2d","21.41"],["\u897f\u5357","11.62"],["\u534e\u5357","9.61"],["\u4e1c\u5317","8.47"],["\u5176\u4ed6\u4e1a\u52a1\u603b\u8ba1",18.33]]}},"2017-12-31":{"YYSR":{"1":[["\u751f\u7269\u5236\u5242","32257.45"]],"2":[["\u7279\u5c14\u6d25","11841.51"],["\u6d3e\u683c\u5bbe","8687.75"],["\u7279\u5c14\u5eb7","7162.63"],["\u7279\u5c14\u7acb","4565.56"]],"3":[["\u534e\u4e1c","10714.00"],["\u534e\u4e2d","5392.65"],["\u4e1c\u5317","3550.92"],["\u534e\u5317","3422.05"],["\u897f\u5317","3019.73"],["\u5176\u4ed6\u4e1a\u52a1\u603b\u8ba1",6158.09]]},"YYCB":{"1":[["\u751f\u7269\u5236\u5242","4164.46"]],"2":[["\u7279\u5c14\u6d25","1664.67"],["\u6d3e\u683c\u5bbe","1456.59"],["\u7279\u5c14\u5eb7","466.65"],["\u7279\u5c14\u7acb","576.54"]],"3":[["\u534e\u4e1c","1471.51"],["\u534e\u4e2d","595.74"],["\u4e1c\u5317","349.13"],["\u534e\u5317","462.39"],["\u897f\u5317","310.22"],["\u5176\u4ed6\u4e1a\u52a1\u603b\u8ba1",975.47]]},"LRBL":{"1":[["\u751f\u7269\u5236\u5242","100.00"]],"2":[["\u7279\u5c14\u6d25","36.23"],["\u6d3e\u683c\u5bbe","25.74"],["\u7279\u5c14\u5eb7","23.84"],["\u7279\u5c14\u7acb","14.20"]],"3":[["\u534e\u4e1c","32.90"],["\u534e\u4e2d","17.08"],["\u4e1c\u5317","11.40"],["\u534e\u5317","10.54"],["\u897f\u5317","9.64"],["\u5176\u4ed6\u4e1a\u52a1\u603b\u8ba1",18.45]]}}}
{"YYSR":{"chartWrap1":[{"name":"\u751f\u7269\u5236\u5242","timeData":["2019-06-30","2018-12-31","2017-12-31"],"lineData":[31820.39,44616.11,32257.45],"columnData":[100,100,100],"unit":["3.18\u4ebf","4.46\u4ebf","3.23\u4ebf"]}],"chartWrap2":[{"name":"\u6d3e\u683c\u5bbe","timeData":["2019-06-30","2018-12-31","2017-12-31"],"lineData":[14849.84,18736.55,8687.75],"columnData":[46.67,42,26.93],"unit":["1.48\u4ebf","1.87\u4ebf","8687.75\u4e07"]},{"name":"\u7279\u5c14\u6d25","timeData":["2019-06-30","2018-12-31","2017-12-31"],"lineData":[8773.98,12741.22,11841.51],"columnData":[27.57,28.56,36.71],"unit":["8773.98\u4e07","1.27\u4ebf","1.18\u4ebf"]},{"name":"\u7279\u5c14\u5eb7","timeData":["2019-06-30","2018-12-31","2017-12-31"],"lineData":[5655.7,8386.88,7162.63],"columnData":[17.77,18.8,22.2],"unit":["5655.70\u4e07","8386.88\u4e07","7162.63\u4e07"]},{"name":"\u7279\u5c14\u7acb","timeData":["2019-06-30","2018-12-31","2017-12-31"],"lineData":[2540.87,4751.45,4565.56],"columnData":[7.99,10.65,14.15],"unit":["2540.87\u4e07","4751.45\u4e07","4565.56\u4e07"]}],"chartWrap3":[{"name":"\u534e\u4e1c","timeData":["2019-06-30","2018-12-31","2017-12-31"],"lineData":[10262.85,14055.4,10714],"columnData":[32.25,31.5,33.21],"unit":["1.03\u4ebf","1.41\u4ebf","1.07\u4ebf"]},{"name":"\u534e\u4e2d","timeData":["2019-06-30","2018-12-31","2017-12-31"],"lineData":[5823.31,9529.27,5392.65],"columnData":[18.3,21.36,16.72],"unit":["5823.31\u4e07","9529.27\u4e07","5392.65\u4e07"]},{"name":"\u534e\u5317","timeData":["2019-06-30","2017-12-31"],"lineData":[3469.49,3422.05],"columnData":[10.9,10.61],"unit":["3469.49\u4e07","3422.05\u4e07"]},{"name":"\u897f\u5317","timeData":["2019-06-30","2017-12-31"],"lineData":[3434.16,3019.73],"columnData":[10.79,9.36],"unit":["3434.16\u4e07","3019.73\u4e07"]},{"name":"\u534e\u5357","timeData":["2019-06-30","2018-12-31"],"lineData":[3008.86,4249.43],"columnData":[9.46,9.52],"unit":["3008.86\u4e07","4249.43\u4e07"]},{"name":"\u5176\u4ed6\u4e1a\u52a1\u603b\u8ba1","timeData":["2019-06-30","2018-12-31","2017-12-31"],"lineData":[5821.71,7669.24,6158.09],"columnData":[18.29,17.2,19.09],"unit":["5821.71\u4e07","7669.24\u4e07","6158.09\u4e07"]},{"name":"\u897f\u5357","timeData":["2018-12-31"],"lineData":[5424.29],"columnData":[12.16],"unit":["5424.29\u4e07"]},{"name":"\u4e1c\u5317","timeData":["2018-12-31","2017-12-31"],"lineData":[3688.48,3550.92],"columnData":[8.27,11.01],"unit":["3688.48\u4e07","3550.92\u4e07"]}]},"YYCB":{"chartWrap1":[{"name":"\u751f\u7269\u5236\u5242","timeData":["2019-06-30","2018-12-31","2017-12-31"],"lineData":[3946.98,5584.6,4164.46],"columnData":[100,100,100],"unit":["3946.98\u4e07","5584.60\u4e07","4164.46\u4e07"]}],"chartWrap2":[{"name":"\u6d3e\u683c\u5bbe","timeData":["2019-06-30","2018-12-31","2017-12-31"],"lineData":[2311.5,2894.46,1456.59],"columnData":[58.56,51.83,34.98],"unit":["2311.50\u4e07","2894.46\u4e07","1456.59\u4e07"]},{"name":"\u7279\u5c14\u6d25","timeData":["2019-06-30","2018-12-31","2017-12-31"],"lineData":[998.75,1658.01,1664.67],"columnData":[25.3,29.69,39.97],"unit":["998.75\u4e07","1658.01\u4e07","1664.67\u4e07"]},{"name":"\u7279\u5c14\u5eb7","timeData":["2019-06-30","2018-12-31","2017-12-31"],"lineData":[350.85,486.26,466.65],"columnData":[8.89,8.71,11.21],"unit":["350.85\u4e07","486.26\u4e07","466.65\u4e07"]},{"name":"\u7279\u5c14\u7acb","timeData":["2019-06-30","2018-12-31","2017-12-31"],"lineData":[285.88,545.87,576.54],"columnData":[7.24,9.77,13.84],"unit":["285.88\u4e07","545.87\u4e07","576.54\u4e07"]}],"chartWrap3":[{"name":"\u534e\u4e1c","timeData":["2019-06-30","2018-12-31","2017-12-31"],"lineData":[1449.09,2128.19,1471.51],"columnData":[36.71,38.11,35.33],"unit":["1449.09\u4e07","2128.19\u4e07","1471.51\u4e07"]},{"name":"\u534e\u4e2d","timeData":["2019-06-30","2018-12-31","2017-12-31"],"lineData":[648.19,1172.97,595.74],"columnData":[16.42,21,14.31],"unit":["648.19\u4e07","1172.97\u4e07","595.74\u4e07"]},{"name":"\u534e\u5317","timeData":["2019-06-30","2017-12-31"],"lineData":[404.71,462.39],"columnData":[10.25,11.1],"unit":["404.71\u4e07","462.39\u4e07"]},{"name":"\u897f\u5317","timeData":["2019-06-30","2017-12-31"],"lineData":[352.15,310.22],"columnData":[8.92,7.45],"unit":["352.15\u4e07","310.22\u4e07"]},{"name":"\u534e\u5357","timeData":["2019-06-30","2018-12-31"],"lineData":[432.18,499.04],"columnData":[10.95,8.94],"unit":["432.18\u4e07","499.04\u4e07"]},{"name":"\u5176\u4ed6\u4e1a\u52a1\u603b\u8ba1","timeData":["2019-06-30","2018-12-31","2017-12-31"],"lineData":[660.67,515.28,975.47],"columnData":[16.75,9.23,23.42],"unit":["660.67\u4e07","515.28\u4e07","975.47\u4e07"]},{"name":"\u897f\u5357","timeData":["2018-12-31"],"lineData":[887.46],"columnData":[15.89],"unit":["887.46\u4e07"]},{"name":"\u4e1c\u5317","timeData":["2018-12-31","2017-12-31"],"lineData":[381.64,349.13],"columnData":[6.83,8.38],"unit":["381.64\u4e07","349.13\u4e07"]}]},"LRBL":{"chartWrap1":[{"name":"\u751f\u7269\u5236\u5242","timeData":["2019-06-30","2018-12-31","2017-12-31"],"lineData":[100,100,100],"columnData":[100,100,100],"unit":["100.00\u4e07","100.00\u4e07","100.00\u4e07"]}],"chartWrap2":[{"name":"\u6d3e\u683c\u5bbe","timeData":["2019-06-30","2018-12-31","2017-12-31"],"lineData":[44.98,40.59,25.74],"columnData":[44.98,40.59,25.74],"unit":["44.98\u4e07","40.59\u4e07","25.74\u4e07"]},{"name":"\u7279\u5c14\u6d25","timeData":["2019-06-30","2018-12-31","2017-12-31"],"lineData":[27.89,28.4,36.23],"columnData":[27.89,28.4,36.23],"unit":["27.89\u4e07","28.40\u4e07","36.23\u4e07"]},{"name":"\u7279\u5c14\u5eb7","timeData":["2019-06-30","2018-12-31","2017-12-31"],"lineData":[19.03,20.24,23.84],"columnData":[19.03,20.24,23.84],"unit":["19.03\u4e07","20.24\u4e07","23.84\u4e07"]},{"name":"\u7279\u5c14\u7acb","timeData":["2019-06-30","2018-12-31","2017-12-31"],"lineData":[8.09,10.77,14.2],"columnData":[8.09,10.77,14.2],"unit":["8.09\u4e07","10.77\u4e07","14.20\u4e07"]}],"chartWrap3":[{"name":"\u534e\u4e1c","timeData":["2019-06-30","2018-12-31","2017-12-31"],"lineData":[31.62,30.56,32.9],"columnData":[31.62,30.56,32.9],"unit":["31.62\u4e07","30.56\u4e07","32.90\u4e07"]},{"name":"\u534e\u4e2d","timeData":["2019-06-30","2018-12-31","2017-12-31"],"lineData":[18.57,21.41,17.08],"columnData":[18.57,21.41,17.08],"unit":["18.57\u4e07","21.41\u4e07","17.08\u4e07"]},{"name":"\u534e\u5317","timeData":["2019-06-30","2017-12-31"],"lineData":[11,10.54],"columnData":[11,10.54],"unit":["11.00\u4e07","10.54\u4e07"]},{"name":"\u897f\u5317","timeData":["2019-06-30","2017-12-31"],"lineData":[11.06,9.64],"columnData":[11.06,9.64],"unit":["11.06\u4e07","9.64\u4e07"]},{"name":"\u534e\u5357","timeData":["2019-06-30","2018-12-31"],"lineData":[9.24,9.61],"columnData":[9.24,9.61],"unit":["9.24\u4e07","9.61\u4e07"]},{"name":"\u5176\u4ed6\u4e1a\u52a1\u603b\u8ba1","timeData":["2019-06-30","2018-12-31","2017-12-31"],"lineData":[18.52,18.33,18.45],"columnData":[18.52,18.33,18.45],"unit":["18.52\u4e07","18.33\u4e07","18.45\u4e07"]},{"name":"\u897f\u5357","timeData":["2018-12-31"],"lineData":[11.62],"columnData":[11.62],"unit":["11.62\u4e07"]},{"name":"\u4e1c\u5317","timeData":["2018-12-31","2017-12-31"],"lineData":[8.47,11.4],"columnData":[8.47,11.4],"unit":["8.47\u4e07","11.40\u4e07"]}]}}

营业收入 X

单位（%） 单位（万元）
注：通常在中报、年报时披露　
业务名称 营业收入(元) 收入比例 营业成本(元) 成本比例 利润比例 毛利率
按行业 生物制剂 3.18亿 100.00% 3946.98万 100.00% 100.00% 87.60%
按产品 派格宾 1.48亿 46.67% 2311.50万 58.56% 44.98% 84.43%
特尔津 8773.98万 27.57% 998.75万 25.30% 27.89% 88.62%
特尔康 5655.70万 17.77% 350.85万 8.89% 19.03% 93.80%
特尔立 2540.87万 7.99% 285.88万 7.24% 8.09% 88.75%
按地区 华东 1.03亿 32.25% 1449.09万 36.71% 31.62% 85.88%
华中 5823.31万 18.30% 648.19万 16.42% 18.57% 88.87%
华北 3469.49万 10.90% 404.71万 10.25% 11.00% 88.34%
西北 3434.16万 10.79% 352.15万 8.92% 11.06% 89.75%
华南 3008.86万 9.46% 432.18万 10.95% 9.24% 85.64%
东北 2991.41万 9.40% 287.94万 7.30% 9.70% 90.37%
西南 2766.32万 8.69% 362.16万 9.18% 8.63% 86.91%
海外 63.98万 0.20% 10.57万 0.27% 0.19% 83.48%

董事会经营评述

　　1、营业收入的构成及变动趋势分析.
　　报告期内公司营业收入持续增长，主要原因系近年来医药行业保持扩张的发展趋势及2016年公司新产品派格宾的上市；从营业收入构成来看，公司主营业务突出，主营业务收入占公司营业收入的99%以上，其他业务收入主要是试剂销售收入、技术服务收入等，其他业务收入占营业收入比例较小。
　　随着生物技术药品在恶性肿瘤、血液系统疾病、病毒性肝炎等疾病的治疗领域取得突破性进展，生物医药行业销售规模持续高速增长，为中国生物药参与者带来庞大机遇。自2016年新产品派格宾推出以来，派格宾所占比重以及金额均在逐年增加。
　　公司主营业务收入来源于派格宾、特尔津、特尔康、特尔立四种产... 查看全部▼

　　1、营业收入的构成及变动趋势分析.
　　报告期内公司营业收入持续增长，主要原因系近年来医药行业保持扩张的发展趋势及2016年公司新产品派格宾的上市；从营业收入构成来看，公司主营业务突出，主营业务收入占公司营业收入的99%以上，其他业务收入主要是试剂销售收入、技术服务收入等，其他业务收入占营业收入比例较小。
　　随着生物技术药品在恶性肿瘤、血液系统疾病、病毒性肝炎等疾病的治疗领域取得突破性进展，生物医药行业销售规模持续高速增长，为中国生物药参与者带来庞大机遇。自2016年新产品派格宾推出以来，派格宾所占比重以及金额均在逐年增加。
　　公司主营业务收入来源于派格宾、特尔津、特尔康、特尔立四种产品，分产品的销售情况分析如下：
　　（1）聚乙二醇干扰素α-2b注射液（商品名称：“派格宾”）的销售收入分析.
　　公司2016年新上市的产品派格宾是公司自主研发的生物制品国家1类新药，国内第一支具有完全自主知识产权的长效干扰素产品，曾4次获得国家科技部“重大新药创制”科技重大专项的支持，其上市打破了国外进口同类产品垄断中国市场的局面。报告期内，派格宾产品的销售收入呈逐年上涨的趋势，具体分析如下：
　　①派格宾系公司完全自主知识产权的创新专利新药，派格宾受价格招标机制影响较小。2016年派格宾新药刚上市，销售单价较高，2017年、2018年派格宾的销售单价相比2016年略有下降，一是因为派格宾有部分产品通过药房实现销售，药房作为盈利性单位，需要给予药房一定的利润空间；二是公司开展公益项目或课题项目，销售价格较低，如公司2018年与浙江大学合作开展“艾滋病和病毒性肝炎等重大传染病防治”的科技重大专项项目，为项目提供药品优惠，等等。
　　②报告期内随着各省市招标工作逐步开展和公司派格宾营销网络的逐步完善，派格宾的销售数量逐年增加，由2016年的9.87万支增长至2018年的27.35万支。我国肝病用药市场容量巨大，2017年我国肝病用药市场销售额达475.66亿元，2014年至2017年四年的复合增长率为6.26%，未来市场仍保持增长趋势。
　　随着以干扰素为主导产品治疗乙肝临床治愈理念的普及，预计未来几年公司派格宾的销售规模将继续稳定增长，将成为公司一个重要的盈利增长点。
　　（2）重组人粒细胞刺激因子注射液（商品名称：“特尔津”）的销售收入变动分析.
　　特尔津于1999年上市，主要用于癌症化疗以及再生障碍性贫血等原因导致中性粒细胞减少症，促进骨髓移植后的中性粒细胞数升高。目前我国重组人粒细胞刺激因子制剂的市场竞争较为激烈，特尔津主要竞争产品为石药的津优力、齐鲁制药有限公司的瑞白及新瑞白、双鹭药业的立生素等，进口产品有日本协和发酵麒麟株式会社的惠尔血。
　　（3）注射用重组人白介素-11（商品名称：“特尔康”）的销售收入变动分析.
　　特尔康于2005年上市，主要用于实体瘤、非髓性白血病化疗后Ⅲ、Ⅳ度血小板减少症的治疗。目前我国重组人白介素-11制剂市场中，涉及品牌较少，市场竞争结构稳定。报告期公司在加大专业化推广的基础上，特尔康的销量逐年增加，单价有一定降幅，收入逐年增长。
　　（4）注射用重组人粒细胞巨噬细胞刺激因子（商品名称：“特尔立”）的销售收入变动分析.
　　特尔立于1997年首仿上市，主要用于预防和治疗肿瘤放疗或化疗后引起的白细胞减少症以及预防白细胞减少可能潜在的感染并发症，治疗骨髓造血机能障碍及骨髓增生异常综合征，使感染引起的中性粒细胞减少的恢复加快。目前我国重组人粒细胞巨噬细胞刺激因子制剂市场中，涉及品牌较少，市场竞争结构稳定。
　　报告期特尔立的销售收入、销售数量呈增长趋势，销售增长的主要原因是公司在巩固原有血液科与肿瘤科的使用以外，加强了放疗科的学术推广。
　　2、主营业务收入区域分布情况.
　　公司销售主要来源于国内市场，销售占比达到95%以上；公司的海外市场占主营业务收入比重较低，海外销售收入的主要来源是秘鲁，报告期平均占海外销售收入的60%以上。 收起▲

同花顺个股页面 | F10论坛 | 模拟炒股 | 股民学校 | 手机炒股| 联系我们

免责声明:本信息由同花顺金融研究中心提供，仅供参考，同花顺金融研究中心力求但不保证数据的完全准确，如有错漏请以中国证监会指定上市公司信息披露媒体为准，同花顺金融研究中心不对因该资料全部或部分内容而引致的盈亏承担任何责任。用户个人对服务的使用承担风险。同花顺对此不作任何类型的担保。同花顺不担保服务一定能满足用户的要求，也不担保服务不会受中断，对服务的及时性，安全性，出错发生都不作担保。同花顺对在同花顺上得到的任何信息服务或交易进程不作担保。同花顺提供的包括同花顺理财的所有文章，数据，不构成任何的投资建议，用户查看或依据这些内容所进行的任何行为造成的风险和结果都自行负责，与同花顺无关。